

Recombinant Human PD-L1/B7-H1/CD274 Protein (His Tag)

Catalog Number: PKSH033557

Note: Centrifuge before opening to ensure complete recovery of vial contents.


Description

Species	Human
Source	HEK293 Cells-derived Human PD-L1/B7-H1/CD274 protein Phe19-Thr239, with an C-terminal His
Calculated MW	26.3 kDa
Observed MW	34-42 kDa
Accession	Q9NZQ7
Bio-activity	Immobilized Anti-Human PDL1 mAb at 2µg/ml (100 µl/well) can bind Human PD-L1-His. The ED ₅₀ of Human PD-L1-6His is 5.57 ng/ml.

Properties

Purity	> 95 % as determined by reducing SDS-PAGE.
Endotoxin	< 1.0 EU per µg of the protein as determined by the LAL method.
Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80 °C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.
Formulation	Lyophilized from a 0.2 µm filtered solution of 20mM PB, 4% Mannitol, 0.02% Tween 80, pH7.4. Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual.
Reconstitution	Please refer to the printed manual for detailed information.

Data



> 95 % as determined by reducing SDS-PAGE.

Background

CD274; also known as B7-H1 or programmed death ligand 1 (PD-L1); is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1; CD274; B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1 (PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells; PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly; it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.